NCT05708053

Cardio-protective Effect of Metformin in Patients Undergoing PCI

Cardio-protective Effect of Metformin in Patients Undergoing Elective Percutaneous Coronary Intervention

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Future University in Egypt · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a two-arm randomized parallel study. Patients who will be meeting the above-mentioned criteria and agree to take part in the study, were asked to sign an informed consent prior conducting the study. The whole study protocol were presented to the local institutional review board (IRB).

Conditions

• Elective Percutaneous Coronary Intervention
• Ischemic Reperfusion Injury

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 500 mg twice

Timeline

• Start date: 2019-12-09
• Primary completion: 2021-12-09
• Completion: 2024-12-01
• First posted: 2023-02-01
• Last updated: 2023-09-13

Locations

3 sites across 1 country: Egypt